Health services: US Deals 2025 midyear outlook
Health services M&A has weathered a complicated macroeconomic and political environment but, strong subsector growth demonstrates sector durability.
Featured - 4 items
- 100 results
- Reset filters
Loading...
Pharmaceutical and life sciences: US Deals 2025 midyear outlook
Companies are responding with targeted mitigation strategies, while maintaining flexibility as tariff policies continue to evolve.
Health industries quarterly insights: Q2 2025
The health industries quarterly offers insights on accounting and reporting hot topics impacting the industry.
Taking a closer look at the Most Favored Nation Pricing Executive Order
PwC specialists break down MFN drug pricing and what companies should do now to reassess pricing, supply chains, and policy risks.
US GAAP – Issues and solutions for pharmaceutical and life sciences
This publication highlights industry-specific factors to be considered and provides guidance on the most pertinent accounting solutions for the pharmaceutical, life sciences and medical device industry.
Navigating the FDA disruption: 4 key actions for pharma
Explore how pharma and biotech leaders can navigate FDA disruption with smarter submissions, regulatory agility, and global risk mitigation strategies.
Strategic Shifts: Navigating China's Biotech Boom and Its Impact on US Pharma
Explore the rise of China’s biotech industry and what it means for U.S. pharma, from innovation and partnerships to diligence and global strategy.
Strategies to capture value in uncompensated care for hospitals
Learn how hospitals can use reimbursement solutions for uncompensated care through Medicare bad debt reimbursement and hospital cost report strategies.
Navigating the FDA disruption: 4 key actions for pharma
The FDA is facing major disruption. Clinical timelines and pipeline investments may be at risk. Discover four key actions US pharma can take now to stay ahead.
China's rise as a biotech innovation hub: 4 key strategic questions for US biopharma executives
China’s biotech boom presents US pharma with both opportunity and risk. Biopharma leaders must reassess diligence, strategy and geopolitical exposure.
Navigating Healthcare’s Next Chapter Under the Trump Administration
Explore how shifting policies, tariffs, AI, and regulatory changes are reshaping healthcare strategy, innovation, and affordability in 2025.
Health plans: Use provider data management to your advantage
Learn how health plans can turn provider data management into a strategic advantage — improving compliance, reducing costs, and enhancing patient experience.
Loading...
Follow us
